Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2017 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders

- ND0612 head-to-head pilot PK results and ND0701 first-in-man PK results to also be presented - - ND0612 clinical data featured in four additional abstracts - REHOVOT, Israel, May 23, 2017 (GLOBE...
May 11, 2017 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces First Quarter 2017 Financial Results

REHOVOT, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
April 20, 2017 11:00 ET | Source: NeuroDerm Ltd.

NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk

REHOVOT, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
April 10, 2017 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm to Host Investor Day on April 21, 2017

REHOVOT, Israel, April 10, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
March 30, 2017 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results

Files Annual Report on Form 20-F Company to Host Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a...
March 21, 2017 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017

REHOVOT, Israel, March 21, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
March 01, 2017 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting

- Trial 006 demonstrated a statistically significant and clinically meaningful reduction in OFF-time and increase in proportion of patients “ON” by 8:00 am (primary and key secondary endpoints) - -...
February 27, 2017 16:01 ET | Source: NeuroDerm Ltd.

NeuroDerm CEO to Present at Upcoming Investor Conferences

REHOVOT, Israel, Feb. 27, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
January 26, 2017 16:01 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Extraordinary General Meeting of Shareholders

REHOVOT, Israel, Jan. 26, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
January 03, 2017 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017

REHOVOT, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...